ArticleThe Journal of experimental medicine2024
Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients.
Abstract read
In one paragraph
Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.Journal of clinical immunology · 2026Pooled it
- High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.Journal of human immunity · 2026Article
- Prevalence of neutralizing autoantibodies against type I interferon in dengue patients.Journal of human immunity · 2026Article
- Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case-control study.EBioMedicine · 2026Observational
- Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.Immunity · 2026Article
- Article
- Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.Cell · 2026Article
- ISG15 negatively regulates RIPK3-mediated cell death and viral pathogenesis.Cell reports · 2026Article
- Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.Journal of human immunity · 2026Article
- Toward a monogenic architecture of human infections: From 1996 to 2026.Journal of human immunity · 2026Review
- RNA-binding proteins Zfp36l1 and Zfp36l2 protect against premature thymic involution.Cellular & molecular immunology · 2026Article
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.medRxiv : the preprint server for health sciences · 2026Article
- A rare case of breakthrough tick-borne encephalitis in early adolescence after vaccination with four doses of TBE vaccine.New microbes and new infections · 2026Article
- Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.The Journal of experimental medicine · 2026Article
- Autoantibodies neutralizing type 1 interferons in two cohorts of people with HIV.Journal of human immunity · 2026Article
- Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza.The Journal of experimental medicine · 2026Article
- Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Adrian GervaisLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-1083-5787
Astrid Marchal *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0003-0648-8126
Andrea Fortova *Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.ORCID 0009-0003-8701-7867
Michaela Berankova *Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.ORCID 0009-0009-1630-5902
Lenka KrbkovaDepartment of Children's Infectious Diseases, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0002-9834-536X
Martina PychovaDepartment of Infectious Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0003-2691-169X
Jiri SalatLaboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.ORCID 0000-0002-9915-8953
Shuxiang ZhaoSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.ORCID 0000-0001-9185-6813
Nacim KerroucheSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.ORCID 0009-0003-1922-9008
Tom Le VoyerLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-7253-3135
Karin StiasnyMedical University of Vienna, Center for Virology , Vienna, Austria.ORCID 0000-0002-1902-8674
Simon RafflMedical University of Vienna, Center for Virology , Vienna, Austria.ORCID 0009-0001-9125-3892
Anne Schieber PachartClinical Research Department, Hôpitaux Civils de Colmar, Colmar, France.ORCID 0009-0003-2947-3717
Samira Fafi-KremerInstitut de Virologie, Strasbourg University Hospital, Strasbourg University, INSERM Unité Mixte de Recherche (UMR) S1109 , Strasbourg, France.ORCID 0000-0003-3886-7833
Simon GravierInfectious Diseases Department, Hôpitaux Civils, Colmar, France.ORCID 0000-0003-4230-5534
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0001-7379-3484
Laurent AbelLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-7016-6493
Margaret R MacDonaldLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-5177-2068
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3087-8079
Gaia WeissmannDepartment of Pediatrics and Neonatology, F. Tappeiner Hospital, Merano, Italy.ORCID 0000-0002-9157-2340
Tarek Kamal EldinInfectious Disease Unit, Provincial Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.ORCID 0009-0006-4025-2773
Eva RobatscherLaboratory of Microbiology and Virology, SABES-ASDAA, Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.ORCID 0009-0003-1913-5642
Elke Maria ErneInfectious Disease Unit, Provincial Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.ORCID 0000-0002-9295-7998
Elisabetta PaganiLaboratory of Microbiology and Virology, SABES-ASDAA, Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.ORCID 0000-0002-4008-6756
Alessandro Borghesi *Neonatal Intensive Care Unit, San Matteo Research Hospital, Pavia, Italy.ORCID 0000-0002-8773-9144
Anne Puel *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0003-2603-0323
Paul Bastard *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-5926-8437
Aurélie Velay *Institut de Virologie, Strasbourg University Hospital, Strasbourg University, INSERM Unité Mixte de Recherche (UMR) S1109 , Strasbourg, France.ORCID 0000-0002-9174-8959
Martin Martinot *Infectious Diseases Department, Hôpitaux Civils, Colmar, France.ORCID 0000-0003-4524-9064
Yves Hansmann *CHU de Strasbourg, Service des Maladies Infectieuses et Tropicales , Strasbourg, France.ORCID 0000-0001-8903-0027
Judith H Aberle *Medical University of Vienna, Center for Virology , Vienna, Austria.ORCID 0000-0003-1197-3935
Daniel Ruzek *Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.ORCID 0000-0003-4655-2380
Aurélie Cobat *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-7209-6257
Shen-Ying Zhang *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-9449-3672
Jean-Laurent Casanova *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-7782-4169
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunityR01AI124690 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2016 to 2026
$8.3MInborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7MAgence Nationale de la Recherche ANR-10-IAHU-01Battersea & Bowery Advisory GroupBettencourt-Schueller FoundationCzech Ministry of Health NU22-05-00659European UnionFisher Center for Alzheimer's Research FoundationFondation du SouffleFrench Foundation for Medical Research EQU201903007798French Ministry of Higher Education, Research, and Innovation MESRI-COVID-19Grandir - Fonds de solidarité pour l'enfanceHoward Hughes Medical InstituteImagine InstituteInstitut National de la Santé et de la Recherche Médicale UMR_S 1109Italian Ministry of Health RC08061819JPB FoundationMeyer FoundationMinistry of Health PHRCN-17-0382National Institute of Virology and Bacteriology LX22N-PO5103NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI124690NIAID NIH HHS R01 AI163029NIH HHS R01AI163029Paris Cité UniversityRockefeller UniversitySan Matteo Hospital 08061821SCOR Corporate Foundation for ScienceSquare FoundationStavros Niarchos FoundationSt. Giles FoundationStrasbourg UniversityStrasbourg University Hospital PRI 7782
Abstract
Tick-borne encephalitis (TBE) virus (TBEV) is transmitted to humans via tick bites. Infection is benign in >90% of the cases but can cause mild (<5%), moderate (<4%), or severe (<1%) encephalitis. We show here that ∼10% of patients hospitalized for severe TBE in cohorts from Austria, Czech Republic, and France carry auto-Abs neutralizing IFN-α2, -β, and/or -ω at the onset of disease, contrasting with only ∼1% of patients with moderate and mild TBE. These auto-Abs were found in two of eight patients who died and none of 13 with silent infection. The odds ratios (OR) for severe TBE in individuals with these auto-Abs relative to those without them in the general population were 4.9 (95% CI: 1.5-15.9, P < 0.0001) for the neutralization of only 100 pg/ml IFN-α2 and/or -ω, and 20.8 (95% CI: 4.5-97.4, P < 0.0001) for the neutralization of 10 ng/ml IFN-α2 and -ω. Auto-Abs neutralizing type I IFNs accounted for ∼10% of severe TBE cases in these three European cohorts.
Indexed as
Antibodies, NeutralizingAutoantibodiesEncephalitis, Tick-BorneInterferon Type IAdultAgedAustriaCzech RepublicEncephalitis Viruses, Tick-BorneFemaleHumansMaleMiddle AgedAntibodies, NeutralizingAutoantibodiesInterferon Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.